TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type

Experimental and Molecular Pathology

Volumn 95, Issue 2, 2013, Pages 235-241

  Rechsteiner, Markus ^a   Zimmermann, Anne Katrin ^a   Wild, Peter J ^a   Caduff, Rosmarie ^a   von Teichman, Adriana ^a   Fink, Daniel ^a   Moch, Holger ^a   Noske, Aurelia ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

BRAF; Deep sequencing; Epithelial ovarian cancer; KRAS; TP53

Indexed keywords

B RAF KINASE; FORMALDEHYDE; K RAS PROTEIN; PARAFFIN; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CLEAR CELL CARCINOMA; COLLOID CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOMETRIOID CARCINOMA; EXON; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MUTATIONAL ANALYSIS; OVARY CARCINOMA; OVERALL SURVIVAL; PYROSEQUENCING;

BRAF; DEEP-SEQUENCING; EPITHELIAL OVARIAN CANCER; KRAS; TP53;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84884326080     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2013.08.004     Document Type: Article

References (30)

1. Ahmed A.A., Etemadmoghadam D., Temple J., Lynch A.G., Riad M., Sharma R., et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J. Pathol. 2010, 221(1):49-56.
2. Anon Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474(7353):609-615.
3. Auner V., Kriegshauser G., Tong D., Horvat R., Reinthaller A., Mustea A., et al. KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. BMC Cancer 2009, 9:111.
4. Ayhan A., Kurman R.J., Yemelyanova A., Vang R., Logani S., Seidman J.D., et al. Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis. Am. J. Surg. Pathol. 2009, 33(8):1220-1224.
5. Bast R.C., Hennessy B., Mills G.B. The biology of ovarian cancer: new opportunities for translation. Nat. Rev. Cancer 2009, 9(6):415-428.
6. Carter H., Chen S., Isik L., Tyekucheva S., Velculescu V.E., Kinzler K.W., et al. Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res. 2009, 69(16):6660-6667.
7. Cuatrecasas M., Catasus L., Palacios J., Prat J. Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas. Am. J. Surg. Pathol. 2009, 33(4):556-567.
8. Esther S.H., Chiung-Ru L., Yeun-Ting H., Jung-Ta C., Ai-Jane L., Man-Jung H., et al. p53 mutation is infrequent in clear cell carcinoma of the ovary. Gynecol. Oncol. 2001, 80(2):189-193. (Feb).
9. Fallows S., Price J., Atkinson R.J., Johnston P.G., Hickey I., Russell S.E. P53 mutation does not affect prognosis in ovarian epithelial malignancies. J. Pathol. 2001, 194(1):68-75.
10. Forman J.R., Worth C.L., Bickerton G.R., Eisen T.G., Blundell T.L. Structural bioinformatics mutation analysis reveals genotype-phenotype correlations in von Hippel-Lindau disease and suggests molecular mechanisms of tumorigenesis. Proteins 2009, 77(1):84-96.
11. Gerstung M., Beisel C., Rechsteiner M., Wild P., Schraml P., Moch H., et al. Reliable detection of subclonal single-nucleotide variants in tumour cell populations. Nat. Commun. 2012, 3:811.
12. Kolasa I.K., Rembiszewska A., Janiec-Jankowska A., Dansonka-Mieszkowska A., Lewandowska A.M., Konopka B., et al. PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations. Gynecol. Oncol. 2006, 103(2):692-697.
13. Kurman R.J., Shih Ie M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum. Pathol. 2011, 42(7):918-931.
14. Leitao M.M., Soslow R.A., Baergen R.N., Olvera N., Arroyo C., Boyd J. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma. Gynecol. Oncol. 2004, 93(2):301-306.
15. Mayr D., Hirschmann A., Lohrs U., Diebold J. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol. Oncol. 2006, 103(3):883-887.
16. Noske A., Zimmermann A.K., Caduff R., Varga Z., Fink D., Moch H., et al. Alpha-methylacyl-CoA racemase (AMACR) expression in epithelial ovarian cancer. Virchows Arch. 2011, 459(1):91-97.
17. Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012, 460(3):237-249.
18. Rechsteiner M., von Teichman A., Ruschoff J.H., Fankhauser N., Pestalozzi B., Schraml P., et al. KRAS, BRAF, and TP53 deep-sequencing for colorectal carcinoma patient diagnostics. J. Mol. Diagn. 2013, 15(3):299-311.
19. Ryland G.L., Hunter S.M., Doyle M.A., Rowley S.M., Christie M., Allan P.E., et al. RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary. J. Pathol. 2013, 229(3):469-476.
20. Salani R., Kurman R.J., Giuntoli R., Gardner G., Bristow R., Wang T.L., et al. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance. Int. J. Gynecol. Cancer 2008, 18(3):487-491.
21. Sieben N.L., Macropoulos P., Roemen G.M., Kolkman-Uljee S.M., Jan Fleuren G., Houmadi R., et al. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J. Pathol. 2004, 202(3):336-340.
22. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 2012, 62(1):10-29.
23. Singer G., Oldt R., Cohen Y., Wang B.G., Sidransky D., Kurman R.J., et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J. Natl. Cancer Inst. 2003, 95(6):484-486.
24. Singer G., Stohr R., Cope L., Dehari R., Hartmann A., Cao D.F., et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am. J. Surg. Pathol. 2005, 29(2):218-224.
25. Stewart C.J., Leung Y., Walsh M.D., Walters R.J., Young J.P., Buchanan D.D. KRAS mutations in ovarian low-grade endometrioid adenocarcinoma: association with concurrent endometriosis. Hum. Pathol. 2012, 43(8):1177-1183.
26. Vereczkey I., Serester O., Dobos J., Gallai M., Szakacs O., Szentirmay Z., et al. Molecular characterization of 103 ovarian serous and mucinous tumors. Pathol. Oncol. Res. 2011, 17(3):551-559.
27. Wild P.J., Ikenberg K., Fuchs T.J., Rechsteiner M., Georgiev S., Fankhauser N., et al. p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumour aggressiveness in humans. EMBO Mol. Med. 2012, 4(8):808-824.
28. Wong K.K., Tsang Y.T., Deavers M.T., Mok S.C., Zu Z., Sun C., et al. BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas. Am. J. Pathol. 2010, 177(4):1611-1617.
29. Wu R., Hendrix-Lucas N., Kuick R., Zhai Y., Schwartz D.R., Akyol A., et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell 2007, 11(4):321-333.
30. Yemelyanova A., Vang R., Kshirsagar M., Lu D., Marks M.A., Shih Ie M., et al. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod. Pathol. 2011, 24(9):1248-1253.